Aim immunotech announces fda clearance of ind application to evaluate ampligen in phase 2 clinical study for the treatment of post-covid conditions

Company expects to commence patient enrollment and dosing in q1 2023 company expects to commence patient enrollment and dosing in q1 2023
AIM Ratings Summary
AIM Quant Ranking